mefloquine-induced psychosis

mefloquine-induced psychosis

A neuropsychiatric adverse reaction (NAR) affecting 1:10,000 to 1:20,000 users of prophylactic mefloquine, which is more common in women. Mefloquine is contraindicated in patients known to be at risk of seizures or psychiatric disease. NARs account for 1/4 of mefloquine side-effects; most NARs begin within three weeks of beginning mefloquine chemoprophylaxis.

Clinical findings
Vertigo, dizziness, headaches, mood changes.
 
Serious adverse effects
Psychotic episodes, seizures, ataxia, hallucinations, depression.